Agile Therapeutics ROE 2013-2023 | AGRX
Current and historical return on equity (ROE) values for Agile Therapeutics (AGRX) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Agile Therapeutics ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2023-12-31 |
$-0.01B |
$-0.02B |
114.29% |
| 2023-09-30 |
$-0.01B |
$-0.01B |
143.59% |
| 2023-06-30 |
$-0.02B |
$-0.01B |
361.90% |
| 2023-03-31 |
$-0.02B |
$-0.01B |
1333.33% |
| 2022-12-31 |
$-0.03B |
$-0.01B |
-1666.67% |
| 2022-09-30 |
$-0.04B |
$0.01B |
-1025.00% |
| 2022-06-30 |
$-0.05B |
$0.00B |
-990.48% |
| 2022-03-31 |
$-0.07B |
$0.00B |
-604.65% |
| 2021-12-31 |
$-0.07B |
$0.00B |
-384.00% |
| 2021-09-30 |
$-0.07B |
$0.01B |
-233.33% |
| 2021-06-30 |
$-0.07B |
$0.03B |
-157.71% |
| 2021-03-31 |
$-0.06B |
$0.04B |
-107.36% |
| 2020-12-31 |
$-0.05B |
$0.05B |
-73.87% |
| 2020-09-30 |
$-0.04B |
$0.07B |
-57.75% |
| 2020-06-30 |
$-0.03B |
$0.08B |
-46.40% |
| 2020-03-31 |
$-0.02B |
$0.09B |
-43.75% |
| 2019-12-31 |
$-0.02B |
$0.05B |
-57.14% |
| 2019-09-30 |
$-0.02B |
$0.03B |
-64.00% |
| 2019-06-30 |
$-0.02B |
$0.02B |
-70.33% |
| 2019-03-31 |
$-0.02B |
$0.03B |
-76.60% |
| 2018-12-31 |
$-0.02B |
$0.02B |
-80.00% |
| 2018-09-30 |
$-0.02B |
$0.02B |
-75.86% |
| 2018-06-30 |
$-0.03B |
$0.03B |
-74.07% |
| 2018-03-31 |
$-0.03B |
$0.03B |
-78.26% |
| 2017-12-31 |
$-0.03B |
$0.04B |
-78.32% |
| 2017-09-30 |
$-0.03B |
$0.04B |
-72.48% |
| 2017-06-30 |
$-0.03B |
$0.03B |
-72.73% |
| 2017-03-31 |
$-0.03B |
$0.04B |
-64.80% |
| 2016-12-31 |
$-0.03B |
$0.04B |
-54.90% |
| 2016-09-30 |
$-0.03B |
$0.05B |
-56.25% |
| 2016-06-30 |
$-0.03B |
$0.05B |
-62.92% |
| 2016-03-31 |
$-0.03B |
$0.06B |
-67.88% |
| 2015-12-31 |
$-0.03B |
$0.03B |
-78.43% |
| 2015-09-30 |
$-0.03B |
$0.03B |
-80.50% |
| 2015-06-30 |
$-0.03B |
$0.04B |
-69.05% |
| 2015-03-31 |
$-0.03B |
$0.05B |
-57.14% |
| 2014-12-31 |
$-0.02B |
$0.04B |
-50.79% |
| 2014-06-30 |
$-0.01B |
$0.05B |
-66.67% |
| 2014-03-31 |
$-0.01B |
$0.00B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.003B |
$0.020B |
|
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
|
